These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33966648)

  • 1. Realizing Public Rights Through Government Patent Use.
    Kapczynski A
    J Law Med Ethics; 2021; 49(1):34-38. PubMed ID: 33966648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Government and Pharmaceutical Innovation: Looking Back and Looking Ahead.
    Sampat BN
    J Law Med Ethics; 2021; 49(1):10-18. PubMed ID: 33966646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study.
    Treasure CL; Avorn J; Kesselheim AS
    Milbank Q; 2015 Dec; 93(4):761-87. PubMed ID: 26626985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. March-in rights under the Bayh-Dole Act: the NIH's paper tiger?
    O'Brien W
    Seton Hall Law Rev; 2013 Nov; 43(4):1403-32. PubMed ID: 24308083
    [No Abstract]   [Full Text] [Related]  

  • 5. Patents, profits, and the American people--the Bayh-Dole Act of 1980.
    Markel H
    N Engl J Med; 2013 Aug; 369(9):794-6. PubMed ID: 23984726
    [No Abstract]   [Full Text] [Related]  

  • 6. A free market solution for prescription drug crises.
    Baker D
    Int J Health Serv; 2004; 34(3):517-26. PubMed ID: 15346683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patents and innovation in cancer therapeutics: lessons from CellPro.
    Bar-Shalom A; Cook-Deegan R
    Milbank Q; 2002; 80(4):637-76, iii-iv. PubMed ID: 12532643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Bayh-Dole good for developing countries? Lessons from the US experience.
    So AD; Sampat BN; Rai AK; Cook-Deegan R; Reichman JH; Weissman R; Kapczynski A
    PLoS Biol; 2008 Oct; 6(10):e262. PubMed ID: 18959484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bayh-Dole Act: a model for promoting research translation?
    Loewenberg S
    Mol Oncol; 2009 Apr; 3(2):91-3. PubMed ID: 19383372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Columbia University's Axel patents: technology transfer and implications for the Bayh-Dole Act.
    Colaianni A; Cook-Deegan R
    Milbank Q; 2009 Sep; 87(3):683-715. PubMed ID: 19751286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Academic Medical Centers as Innovation Ecosystems: Evolution of Industry Partnership Models Beyond the Bayh-Dole Act.
    Silva PJ; Ramos KS
    Acad Med; 2018 Aug; 93(8):1135-1141. PubMed ID: 29668523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms.
    Sarpatwari A; Kesselheim AS; Cook-Deegan R
    J Health Polit Policy Law; 2022 Dec; 47(6):879-895. PubMed ID: 35877952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dozens of coronavirus drugs are in development - what happens next?
    Ledford H
    Nature; 2020 May; 581(7808):247-248. PubMed ID: 32409766
    [No Abstract]   [Full Text] [Related]  

  • 14. Pool patents to get COVID vaccines and drugs to all.
    Billette de Villemeur E; Dequiedt V; Versaevel B
    Nature; 2021 Mar; 591(7851):529. PubMed ID: 33742180
    [No Abstract]   [Full Text] [Related]  

  • 15. NIH funding for patents that contribute to market exclusivity of drugs approved 2010-2019 and the public interest protections of Bayh-Dole.
    Ledley FD; Cleary EG
    PLoS One; 2023; 18(7):e0288447. PubMed ID: 37494368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intellectual property. University licensing and the Bayh-Dole Act.
    Thursby JG; Thursby MC
    Science; 2003 Aug; 301(5636):1052. PubMed ID: 12933996
    [No Abstract]   [Full Text] [Related]  

  • 17. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayh-Dole: if we knew then what we know now.
    Boettiger S; Bennett AB
    Nat Biotechnol; 2006 Mar; 24(3):320-3. PubMed ID: 16525405
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box.
    Khullar D; Ohn JA; Trusheim M; Bach PB
    N Engl J Med; 2020 Jan; 382(5):473-480. PubMed ID: 31995697
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.